Evidence map›Paper›PMID 21205840›Full record

ReviewRNA (New York, N.Y.)2011

Proofreading and spellchecking: a two-tier strategy for pre-mRNA splicing quality control.

Defne E Egecioglu, Guillaume Chanfreau

Abstract readReview
In one paragraph

Review in RNA (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Integration of mRNP formation and export.Cellular and molecular life sciences : CMLS · 2017
    Review
  9. Article
  10. Article
  11. Introns and gene expression: cellular constraints, transcriptional regulation, and evolutionary consequences.BioEssays : news and reviews in molecular, cellular and developmental biology · 2015
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. RNA helicases in splicing.RNA biology · 2013
    Review
  19. Review
  20. The spliceosome as a target of novel antitumour drugs.Nature reviews. Drug discovery · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Defne E EgeciogluDepartment of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, California 90095-1569, USA.
Guillaume Chanfreau

Funding

THE CONTROL OF GENE EXPRESSION BY EUKARYOTIC RNASE IIIR01GM061518 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHANFREAU, GUILLAUME F · 2000 to 2017
$5.5M
NIGMS NIH HHS GM61518NIGMS NIH HHS R01 GM061518
6 · The paper itself

Abstract

Multi-tier strategies exist in many biochemical processes to ensure a maximal fidelity of the reactions. In this review, we focus on the two-tier quality control strategy that ensures the quality of the products of the pre-mRNA splicing reactions catalyzed by the spliceosome. The first step in the quality control process relies on kinetic proofreading mechanisms that are internal to the spliceosome and that are performed by ATP-dependent RNA helicases. The second quality control step, spellchecking, involves recognition of unspliced pre-mRNAs or aberrantly spliced mRNAs that have escaped the first proofreading mechanisms, and subsequent degradation of these molecules by degradative enzymes in the nucleus or in the cytoplasm. This two-tier quality control strategy highlights a need for high fidelity and a requirement for degradative activities that eliminate defective molecules. The presence of multiple quality control activities during splicing underscores the importance of this process in the expression of genetic information.

Indexed as

AnimalsHumansRNA PrecursorsRNA Processing, Post-TranscriptionalRNA SplicingRNA Precursors

Identifiers

PMID21205840
PMCPMC3039138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.